Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
-
- P. Joly
- Department of Dermatology Rouen University Hospital and INSERM U905 Centre de référence des maladies bulleuses autoimmunes Normandie University Rouen France
-
- B. Horvath
- Department of Dermatology University Medical Center Groningen Center for Blistering Diseases University of Groningen Groningen the Netherlands
-
- Α Patsatsi
- Autoimmune Bullous Diseases Unit 2nd Dermatology Department Papageorgiou General Hospital Αristotle University School of Medicine Thessaloniki Greece
-
- S. Uzun
- Department of Dermatology Akdeniz University Faculty of Medicine Antalya Turkey
-
- R. Bech
- Department of Dermatology Aarhus University Hospital Aarhus Denmark
-
- S. Beissert
- Department of Dermatology University Hospital Carl Gustav Carus Dresden Germany
-
- R. Bergman
- Department of Dermatology Rambam Health Care Campus and The Ruth and Bruce Rappaport Faculty of Medicine Haifa Israel
-
- P. Bernard
- University of Reims‐Champagne‐Ardenne Reims France
-
- L. Borradori
- Department of Dermatology University Hospital of Bern University of Bern Bern Switzerland
-
- M. Caproni
- Department of Health Sciences Section of Dermatology USL Toscana Centro Rare Diseases Unit European Reference Network‐Skin Member University of Florence Florence Italy
-
- F. Caux
- Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL Avicenne Hospital AP‐HP University Paris 13 Bobigny France
-
- G. Cianchini
- Department of Dermatology Cristo Re Hospital Rome Italy
-
- M. Daneshpazhooh
- Autoimmune Bullous Diseases Research Center Department of Dermatology Razi Hospital Tehran University of Medical Sciences Tehran Iran
-
- D De
- Department of Dermatology Postgraduate Institute of Medical Education and Research Chandigarh India
-
- M. Dmochowski
- Autoimmune Blistering Dermatoses Section Department of Dermatology Poznan University of Medical Sciences Poznan Poland
-
- K. Drenovska
- Department of Dermatology Medical University Sofia Bulgaria
-
- J. Ehrchen
- Department of Dermatology University of Münster Münster Germany
-
- C. Feliciani
- Dermatology unit Azienda ospedaliero ‐universitaria Universita di Parma Parma Italy
-
- M. Goebeler
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg Würzburg Germany
-
- R. Groves
- St John's Institute of Dermatology London UK
-
- C. Guenther
- Department of Dermatology University Hospital Technical University Dresden Dresden Germany
-
- S. Hofmann
- Department of Dermatology, Allergy and Dermatosurgery Helios University Hospital Wuppertal University Witten Herdecke Germany
-
- D. Ioannides
- 1st Department of Dermatology‐Venereology Hospital of Skin and Venereal Diseases Aristotle University Medical School Thessaloniki Greece
-
- C. Kowalewski
- Department Dermatology and Immunodermatology Medical University of Warsaw Warsaw Poland
-
- R. Ludwig
- Department of Dermatology University Hospital Technical University Dresden Dresden Germany
-
- Y.L. Lim
- National Skin Centre Singapore Singapore
-
- B. Marinovic
- Department of Dermatology and Venereology University Hospital Centre Zagreb School of Medicine University of Zagreb Zagreb Croatia
-
- A.V. Marzano
- Dermatology Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan Italy
-
- J.M. Mascaró
- Department of Dermatology Hospital Clínic de Barcelona Universitat de Barcelona Barcelona Spain
-
- D. Mimouni
- Department of Dermatology Rabin Medical Center petha‐Tikwa and Sackler School of Medicine Tel Aviv University Tel aviv Israel
-
- D.F. Murrell
- Department of Dermatology St George Hospital University of NSW Sydney NSW Australia
-
- C. Pincelli
- DermoLab Institute of Dermatology University of Modena and Reggio Emilia Modena Italy
-
- C.P. Squarcioni
- Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL Avicenne Hospital AP‐HP University Paris 13 Bobigny France
-
- M. Sárdy
- Department of Dermatology, Venereology, and Dermatooncology Semmelweis University Budapest Hungary
-
- J. Setterfield
- Department of Oral Medicine St John's Institute of Dermatology; Guy's and St Thomas' NHS Foundation Trust London UK
-
- E. Sprecher
- Division of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
-
- S. Vassileva
- Department of Dermatology Medical University Sofia Bulgaria
-
- K. Wozniak
- Department of Dermatology and Immunodermatology Medical University of Warsaw Warsaw Poland
-
- S. Yayli
- Department of Dermatology Karadeniz Technical University Faculty of Medicine Trabzon Turkey
-
- G. Zambruno
- Genetics and rare Disease Research Division Bambino Gesù Children’s Hospital IRCCS Rome Italy
-
- D. Zillikens
- Department of Dermatology and Lübeck Institute of Experimental Dermatology (LIED) University of Lübeck Lübeck Germany
-
- M. Hertl
- Department of Dermatology University of Marburg Marburg Germany
-
- E. Schmidt
- Department of Dermatology and Lübeck Institute of Experimental Dermatology (LIED) University of Lübeck Lübeck Germany
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first‐line treatment for moderate and severe pemphigus vulgaris in Europe and the United States.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>The <jats:italic>Autoimmune blistering diseases</jats:italic> Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.</jats:p></jats:sec>
収録刊行物
-
- Journal of the European Academy of Dermatology and Venereology
-
Journal of the European Academy of Dermatology and Venereology 34 (9), 1900-1913, 2020-08-24
Wiley
- Tweet
キーワード
- AZATHIOPRINE
- AUTOIMMUNE BULLOUS DISEASE
- MULTICENTER
- Academies and Institutes
- Guidelines as Topic
- DESMOGLEIN 1
- Dermatology
- THERAPY
- Europe
- DOUBLE-BLIND
- IMMUNOADSORPTION
- Venereology
- Humans
- RITUXIMAB
- COMBINATION
- pemphigus vulgaris, pemphigus foliates, guidelines, management
- MYCOPHENOLATE-MOFETIL
- Pemphigus
詳細情報 詳細情報について
-
- CRID
- 1360298759593526016
-
- ISSN
- 14683083
- 09269959
-
- PubMed
- 33713787
-
- データソース種別
-
- Crossref
- OpenAIRE
